Biogen stock (US09062X1037): closes $5.3B Apellis deal

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding EMPAVELI and SYFOVRE and a new $2 billion term loan to fund the transaction.

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, a move that adds EMPAVELI and SYFOVRE to its portfolio and gives the company a larger presence in rare disease markets that matter to U.S. investors. The closing was disclosed in a May 14 filing with the SEC, which said the deal was financed partly with a new $2 billion term loan.

The stock market reaction was not included in the filing, but the transaction matters because Biogen is using capital and debt to expand beyond neuroscience into a broader commercial platform. According to SEC filing as of 05/14/2026, the deal closed after a tender offer that brought in about 82.4% of Apellis shares.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Biogen Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: United States
• Key revenue drivers: Neurology and rare-disease therapies
• Home exchange/listing venue: Nasdaq: BIIB
• Trading currency: USD

Biogen’s core business model

Biogen develops and commercializes medicines for serious diseases, with a long-standing focus on neurology. For U.S. investors, that makes the company part of a large health-care segment where pricing, reimbursement, and clinical data can move sentiment quickly.

The Apellis transaction broadens that model. Apellis’ EMPAVELI and SYFOVRE add marketed products outside Biogen’s historical center of gravity, which can help reduce dependence on a narrower drug portfolio. The company said the acquisition was structured with cash, a CVR component, and new debt financing.

Main revenue and product drivers for Biogen

Biogen’s core commercial franchise still rests on therapies tied to neurological disease, but the company has been seeking ways to stabilize growth as older products mature. That is why a deal like Apellis can matter beyond headline size: it adds revenue streams that are already in market rather than early-stage pipeline assets.

In the filing, Biogen said Apellis generated $689 million in 2025 net product revenue from EMPAVELI and SYFOVRE. Biogen also said the transaction is expected to be accretive to non-GAAP diluted EPS in 2027, although integration execution and milestone payments tied to the CVR remain variables.

Apellis shares were tendered at about 82.4% of outstanding stock before closing, according to the SEC filing, and the deal values the target at roughly $5.3 billion before any CVR payouts. That scale is meaningful for Biogen because it signals a willingness to use balance-sheet capacity to reshape the company’s product mix.

Conclusion

Biogen’s Apellis acquisition is a strategic capital-allocation story as much as a growth story. The deal gives the company two marketed rare-disease therapies and a larger revenue base, while also adding debt and integration risk. For U.S. investors, the key question now is whether the added products can support a steadier earnings profile as Biogen works through its next phase of growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.